Meloxicam reduces lipopolysaccharide-induced degeneration of dopaminergic neurons in the rat substantia nigra pars compacta

Neuroscience Letters

Volumn 460, Issue 2, 2009, Pages 121-125

  Sui, Yi ^a   Stanić, Davor ^a   Tomas, Doris ^a   Jarrott, Bevyn ^a   Horne, Malcolm K ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cyclooxygenase 2; Lipopolysaccharide; Meloxicam; Microglia; Parkinson's disease

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; LIPOPOLYSACCHARIDE; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME INHIBITION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICROGLIA; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

ANIMALS; ANTIGENS, CD11B; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOPAMINE; LIPOPOLYSACCHARIDES; MALE; NERVE DEGENERATION; NEURONS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; THIAZINES; THIAZOLES; TYROSINE 3-MONOOXYGENASE;

EID: 67349152639     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.05.033     Document Type: Article

References (34)

1. Akiyama H., and McGeer P.L. Brain microglia constitutively express beta-2 integrins. J. Neuroimmunol. 30 (1990) 81-93
2. Arimoto T., and Bing G.Y. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 12 (2003) 35-45
3. Asanuma M., and Miyazaki I. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. Curr. Pharm. Des. 14 (2008) 1428-1434
4. Bauer M.K.A., Lieb K., SchulzeOsthoff K., Berger M., GebickeHaerter P.J., Bauer J., and Fiebich B.L. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem. 243 (1997) 726-731
5. Chae S.W., Kang B.Y., Hwang O., and Choi H.J. Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells. Neurosci. Lett. 436 (2008) 205-209
6. Chen H.L., Zhang S.M.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60 (2003) 1059-1064
7. Choi S.H., Joe E.H., Kim S.U., and Jin B.K. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J. Neurosci. 23 (2003) 5877-5886
8. Di Matteo V., Pierucci M., Di Giovanni G., Di Santo A., Poggi A., Benigno A., and Esposito E. Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res. 1095 (2006) 167-177
9. Dutta G., Zhang P., and Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol. 22 (2008) 453-464
10. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., and Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205 (2007) 295-312
11. Feng Z.H., Wang T.G., Li D.D., Fung P., Wilson B.C., Liu B., Ali S.F., Langenbach R., and Hong J.S. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329 (2002) 354-358
12. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., and Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81 (2002) 1285-1297
13. Herrera A.J., Castano A., Venero J.L., Cano J., and Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7 (2000) 429-447
14. Hetier E., Ayala J., Denefle P., Bousseau A., Rouget P., Mallat M., and Prochiantz A. Brain macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro. J. Neurosci. Res. 21 (1988) 391-397
15. Hirsch E.C., and Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 8 (2009) 382-397
16. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., and Hirsch E.C. Fc epsilon RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999) 3440-3447
17. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., and Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20 (2000) 6309-6316
18. Klivenyi P., Gardian G., Calingasan N.Y., Yang L.C., and Beal M.F. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Mol. Neurosci. 21 (2003) 191-198
19. Lee S.H., Soyoola E., Chanmugam P., Hart S., Sun W.Q., Zhong H., Liou S., Simmons D., and Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 267 (1992) 25934-25938
20. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., Volpe J.J., and Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8514-8519
21. Li Z., Choi D.-Y., Shin E.-J., Hunter R.L., Jin C.H., Wie M.-B., Kim M.S., Park S.J., Bing G., and Kim H.-C. Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci. Lett. 445 (2008) 1-6
22. Litteljohn D., Mangano E.N., and Hayley S. Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur. J. Neurosci. 28 (2008) 707-716
23. McGeer P.L., Itagaki S., Akiyama H., and McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24 (1988) 574-576
24. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
25. Mogi M., Harada M., Kondo T., Riederer P., and Nagatsu T. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 9 (1995) 87-92
26. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C., Mahler J.F., Kluckman K.D., Ledford A., Lee C.A., and Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83 (1995) 473-482
27. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., and Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57 (2005) 168-175
28. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (2005), Elsevier Academic Press, San Diego
29. Sairam K., Saravanan K.S., Banerjee R., and Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res. 966 (2003) 245-252
30. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., and Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13313-13318
31. Solovjov D.A., Pluskota E., and Plow E.F. Distinct roles for the alpha and beta subunits in the functions of integrin alpha(M)beta(2). J. Biol. Chem. 280 (2005) 1336-1345
32. Stanic D., Finkelstein D.I., Bourke D.W., Drago J., and Horne M.K. Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur. J. Neurosci. 18 (2003) 1175-1188
33. Teismann P., and Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39 (2001) 167-174
34. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5473-5478